New Risk • Jul 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 65% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£2.9m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 45% per year over the past 5 years. Shareholders have been substantially diluted in the past year (65% increase in shares outstanding). Revenue is less than US$1m (UK£129k revenue, or US$175k). Market cap is less than US$10m (UK£1.01m market cap, or US$1.36m). Board Change • May 20
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. No independent directors (6 non-independent directors). Non-Executive Director Jeremy Woodgate is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Anuncio • Dec 16
Vault Ventures Plc has completed a Follow-on Equity Offering in the amount of £0.555 million. Vault Ventures Plc has completed a Follow-on Equity Offering in the amount of £0.555 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 45,500,000
Price\Range: £0.01
Security Features: Attached Warrants
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 10,000,000
Price\Range: £0.01
Security Features: Attached Warrants
Transaction Features: Subsequent Direct Listing Anuncio • Nov 21
Vault Ventures plc Confirms the Alpha Launch Phase of vSignal.ai, Is Commence on 24 November 2025 Vault Ventures Plc confirmed that the Alpha launch phase of vSignal.ai, is scheduled to commence on 24 November 2025. The Alpha launch is the first stage of external testing following completion of core development. This controlled release will enable the Company to validate platform performance and gather structured user feedback ahead of broader rollout. Objectives of the Alpha Phase: Evaluate platform stability and data accuracy under live conditions. Assess user experience and interface performance across devices. Capture structured feedback to inform feature refinement and pre-launch messaging. Access to the Alpha will initially be provided to a limited cohort comprising existing shareholders, selected industry experts, and recognized commentators within the crypto and digital-asset sector. Individuals wishing to register their interest in the Alpha or subsequent testing phases may join the waitlist at vSignal.ai and will be notified by email as access becomes available. Participants will be notified and directed, via email, to a designated area within the Company's Investor Hub for the submission of observations and usability feedback. Feedback gathered during the Alpha will inform development priorities ahead of the Beta phase. Board Change • Oct 27
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). Non-Executive Director Jeremy Woodgate is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Anuncio • Oct 17
Vault Ventures plc Provides an Update on the Development of Its Proprietary Product, vSignal.ai Vault Ventures Plc provided an update on the development of its proprietary product, vSignal.ai. This announcement marks the completion of the platform's second development cycle. The goal of this cycle was to bring together all major components of the platform into a fully integrated and operational system in preparation for deployment. Infrastructure ready for scale: vSignal.ai is now live across its full cloud environment, providing a secure and scalable foundation, a key preparatory step as the product moves towards launch. Seamless user access: Secure login and sign-up processes, including Google and email authentication with verification, are now fully operational. Dynamic content experience: The homepage now supports different content or features depending on a user's access level, allowing the Company to control who sees what during testing. AI-driven insight engine: Live news and data feeds are powered by CryptoPanic and Gemini AI, which automatically summarises and prioritises market updates for users. Contextual signal generation: Perplexity AI has been integrated to surface relevant news based on macroeconomic data trends, helping users understand why key indicators are moving and delivering early trading and investment signals. Comprehensive data coverage: Historical and live macroeconomic and cryptocurrency data are now fully integrated, supporting deeper, context-rich analysis. Smarter user interface: Updated layouts, modals and interactive components improve navigation and data visibility, particularly on mobile devices. Anuncio • Jul 30
Vault Ventures Plc (OFEX:VULT) signed non-binding heads of terms to acquire Kingbridge Capital Ltd. Vault Ventures Plc (OFEX:VULT) signed non-binding heads of terms to acquire Kingbridge Capital Ltd on July 29, 2025. The Proposed Acquisition is expected to be an all-share deal. Subject to satisfactory due diligence, appointment of Kieran King, current shareholder and director of Kingbridge, as Non-Executive Director to the Board of Vault.
The Proposed Acquisition is subject to, among others, completion of satisfactory legal and commercial due diligence and execution of a binding share purchase agreement.
Nick Michaels of Alfred Henry Corporate Finance Limited acted as financial advisor to Vault Ventures Plc. Anuncio • Jul 28
Vault Ventures Plc, Annual General Meeting, Aug 19, 2025 Vault Ventures Plc, Annual General Meeting, Aug 19, 2025. Location: the offices of blake morgan llp, 6 new street square, ec4a 3dj, United Kingdom Anuncio • Jul 09
Vault Ventures Plc has completed a Follow-on Equity Offering in the amount of £0.45 million. Vault Ventures Plc has completed a Follow-on Equity Offering in the amount of £0.45 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,250,000,046
Price\Range: £0.0002
Transaction Features: Regulation S Anuncio • Jul 04
Vault Ventures Plc (OFEX:VULT) completed the acquisition of System7 Ventures Limited for £1 million. Vault Ventures Plc (OFEX:VULT) signed non-binding heads of terms to acquire System7 Ventures Limited in an all-share deal valued at £1 million on June 30, 2025. Nicolas Baxter, CEO of System7, to join the Board of Vault Ventures Plc. The parties are currently conducting legal and commercial due diligence and, subject to satisfactory outcomes for both sides, will proceed to finalise a Share Purchase Agreement.
Alfred Henry Corporate Finance Ltd acted as financial advisor for Vault Ventures Plc.
Vault Ventures Plc (OFEX:VULT) completed the acquisition of System7 Ventures Limited for £1 million on July 3, 2025. The total consideration for the Acquisition is to be settled through the issuance of new ordinary shares of £0.0001 each in the Company. The Consideration will be satisfied in multiple tranches, with the first tranche comprising 10% of the Consideration, to be fulfilled by the immediate issuance of 500,000,000 Consideration Shares, to be issued at a price of 0.02p per share. The balance of the Consideration is structured as an earn-out and will be satisfied through further issuances of ordinary shares. As previously announced, Nicolas Baxter, CEO of System7, is expected to join the Board. His appointment is subject to the completion of customary due diligence checks by the Company's advisers. Anuncio • Jul 02
Vault Ventures Plc (OFEX:VULT) signed non-binding heads of terms to acquire System7 Ventures Limited in a transaction valued at £1 million. Vault Ventures Plc (OFEX:VULT) signed non-binding heads of terms to acquire System7 Ventures Limited in a transaction valued at £1 million on June 30, 2025. Nicolas Baxter, CEO of System7, to join the Board of Vault Ventures Plc. The parties are currently conducting legal and commercial due diligence and, subject to satisfactory outcomes for both sides, will proceed to finalise a Share Purchase Agreement. Anuncio • Jun 19
Vault Ventures Plc has completed a Follow-on Equity Offering in the amount of £0.25 million. Vault Ventures Plc has completed a Follow-on Equity Offering in the amount of £0.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,388,888,889
Price\Range: £0.00018
Transaction Features: Regulation S Anuncio • Jun 17
Vault Ventures Plc has filed a Follow-on Equity Offering in the amount of £0.1 million. Vault Ventures Plc has filed a Follow-on Equity Offering in the amount of £0.1 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 555,555,556
Price\Range: £0.00018 New Risk • Feb 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£887.3k market cap, or US$1.11m). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). New Risk • Jan 24
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£589.9k market cap, or US$732.4k). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). New Risk • Jul 09
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (over 10x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (UK£385.0k market cap, or US$493.3k). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Anuncio • Feb 15
Pharma C Investments PLC has completed a Follow-on Equity Offering in the amount of £0.105 million. Pharma C Investments PLC has completed a Follow-on Equity Offering in the amount of £0.105 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 210,000,000
Price\Range: £0.0005
Transaction Features: Subsequent Direct Listing New Risk • Dec 27
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (UK£431.8k market cap, or US$552.5k). Anuncio • Sep 09
Pharma C Investments PLC, Annual General Meeting, Sep 27, 2023 Pharma C Investments PLC, Annual General Meeting, Sep 27, 2023, at 10:00 Coordinated Universal Time. Location: offices of Hill Dickinson LLP Liverpo0L United Kingdom Agenda: To consider THAT Gavin Hilary Sathianathan be removed as director of the Company with immediate effect; to consider THAT Paul Ryan be appointed as director of the Company; and to consider THAT Noel Lyons be appointed as a director of the Company. Anuncio • Nov 19
Pharma C Investments PLC, Annual General Meeting, Dec 16, 2022 Pharma C Investments PLC, Annual General Meeting, Dec 16, 2022, at 11:00 Coordinated Universal Time. Location: at the offices of Hill Dickinson LLP London United Kingdom 
